EFFECTS OF RN316 (PF-04950615), A HUMANIZED IGG2ΔA MONOCLONAL ANTIBODY BINDING PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9, ON LIPOPROTEIN PARTICLES IN HYPERCHOLESTEROLEMIC SUBJECTS  by Wan, Hong et al.
Prevention
E1387
JACC March 12, 2013
Volume 61, Issue 10
effecTs of rn316 (pf-04950615), a humanized igg2Δa monoclonal anTiBody 
Binding proproTein converTase suBTilisin kexin Type 9, on lipoproTein parTicles in 
hypercholesTerolemic suBjecTs
Oral Contributions
West, Room 2006
Sunday, March 10, 2013, 8:15 a.m.-8:30 a.m.
Session Title: Prevention: Novel Investigations in Lipidology
Abstract Category: 24. Prevention: Clinical
Presentation Number: 919-4
Authors: Hong Wan, Barry Gumbiner, Tenshang Joh, Chandrasekhar Udata, Philippe Forgues, Pamela D. Garzone, Pfizer Inc, South San Francisco, CA, 
USA, San Diego, CA, USA
Background: RN316 binds to Proprotein Convertase Subtilisin Kexin type 9 (PCSK9), preventing PCSK9-mediated down-regulation of the low 
density lipoprotein (LDL) receptor (R), improving LDL cholesterol (C) clearance from serum, and reducing LDL-C levels. High concentrations of small 
LDL particles contribute to atherosclerosis. The effects of RN316 on LDL, VLDL and HDL particles were evaluated in hypercholesterolemic (HC) 
subjects.
methods: Nuclear Magnetic Resonance spectroscopy analysis was performed on blood samples collected at baseline and after dosing in three 
double-blind, placebo (PBO)-controlled, randomized studies. In Study #1, 67 HC subjects with LDL-C ≥ 130 mg/dL were treated with 0.25, 0.5, 1 
and 1.5 mg/kg RN316 monotherapy intravenously (IV) or PBO every week for 4 weeks. In Study #2, 90 HC subjects with LDL-C ≥ 100 mg/dL on 
statins were treated with 0.25, 1, 3 & 6 mg/kg RN316 IV or PBO every 4 weeks. In Study #3, 45 HC subjects with LDL-C ≥ 80 mg/dL on statins were 
treated with 1 or 3 mg/kg RN316 IV or PBO every 4 weeks. Lipoprotein particle concentrations were derived for spectrally distinct VLDL, LDL and HDL 
subclasses. Mass-weight average particle diameters were calculated.
results: 
Parameters Adjusted Mean % Change From Baseline (CFB)b
Day 36a (Study #1) Day 71a (Study #2 and #3)
RN316 Groups
(Number of subjectse)
Placebo 
(n=12)
0.25 mg/
kg (n=13)
0.5 mg/kg 
(n=13)
1 mg/kg 
(n=12)
1.5 mg/kg 
(n=14)
Placebof 
(n=31)
0.25 mg/
kg (n=14)
1 mg/kgf 
(n=32)
3 mg/kgf 
(n=33)
6 mg/kg 
(n=15)
VLDL/Chylomicron Particles 
(nmol/L)
32.4c -7.6d -51.3cd -32.8cd -44.3cd -11.9 44.4 -0.74 -31.1 -31.0
LDL Particles (nmol /L) -1.3 -17.8cd -51.2cd -56.6cd -59.0cd 0.2 -12.4 -44.6cd -47.3cd -57.4cd
Small LDL Particles (nmol /L) 8.5 -9.3 -57.6cd -50.9cd -68.5cd 14.3 -13.1d -42.1cd -54.6cd -58.8cd
HDL Particles (umol /L) 3.9 11.1c 8.3c 9.3c 14.8cd -0.8 0.9 5.8cd 9.5cd 11.9cd
VLDL Particle Size (nm) 7.8 7.5 12.1c 15.6c 12.4c 9.1c 3.9 1.4d 4.8 10.2c
HDL Particle Size (nm) 0.6 0.8 1.0 1.8c 1.5c -0.5 0.3 0.8cd 1.0cd 0.3
LDL Particle Size (nm) -1.2 -0.4 1.6cd 0.3 1.1d -0.8 0.7 1.5cd 2.1cd 2.8cd
a. Day 36 and Day 71 were two weeks after last dose in respective studies; b. obtained from ANCOVA model on the CFB with baseline levels as an covariant and 
treatment as a factor; c. p-Value for % CFB < 0.05; d. p-Value for % CFB vs Placebo < 0.05; e. Number of treated subjects with both baseline and Day 36 or Day 71 
data available for analysis; f. Pooled data from Study #2 and #3.
conclusions: RN316 treatments led to significant reductions in VLDL, LDL and small LDL particle concentrations, small increases in HDL particle 
concentrations and small increases in particle sizes. The effects of RN316 are consistent with its mechanism of blocking PCSK9-mediated down-
regulation of LDLR.
